Gloria González Aseguinolaza-rekin lankidetzan egindako argitalpenak (24)

2024

  1. GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model

    Translational Neurodegeneration

2022

  1. High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease

    Molecular Therapy - Methods and Clinical Development, Vol. 26, pp. 98-106

2021

  1. Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis

    Molecular Therapy - Methods and Clinical Development, Vol. 22, pp. 210-221

  2. Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 585-602

2019

  1. Danio rerio as model organism for adenoviral vector evaluation

    Genes, Vol. 10, Núm. 12

  2. Liver Expression of a MiniATP7B Gene Results in Long-Term Restoration of Copper Homeostasis in a Wilson Disease Model in Mice

    Hepatology, Vol. 70, Núm. 1, pp. 108-126

2018

  1. Brain copper storage after genetic long-term correction in a mouse model of Wilson disease

    Neurology: Genetics, Vol. 4, Núm. 3

  2. Visualization of the therapeutic efficacy of a gene correction approach in Wilson's disease by laser-ablation inductively coupled mass spectrometry

    Journal of Hepatology

2017

  1. Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularis

    Human Gene Therapy Clinical Development, Vol. 28, Núm. 2, pp. 68-73

2016

  1. A versatile vector for in vivo monitoring of type I interferon induction and signaling

    PLoS ONE, Vol. 11, Núm. 3

  2. Long-term metabolic correction of Wilson's disease in a murine model by gene therapy

    Journal of Hepatology, Vol. 64, Núm. 2, pp. 419-426

2015

  1. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model

    Molecular Cancer, Vol. 14, Núm. 1

  2. Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver

    Liver International, Vol. 35, Núm. 4, pp. 1274-1289

2013

  1. Cytokines for the treatment of gastrointestinal cancers: Clinical experience and new perspectives

    Expert Opinion on Investigational Drugs, Vol. 22, Núm. 7, pp. 827-841

2012

  1. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B

    Hepatology, Vol. 56, Núm. 2, pp. 474-483

2011

  1. Gene therapy of liver cancer: An update

    Journal Africain du Cancer, Vol. 3, Núm. 3, pp. 180-192

  2. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice

    Gut, Vol. 60, Núm. 3, pp. 341-349

  3. Self-inactivating helper virus for the production of high-capacity adenoviral vectors

    Gene Therapy, Vol. 18, Núm. 11, pp. 1025-1033

  4. Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice

    Molecular Therapy, Vol. 19, Núm. 2, pp. 243-250

2010

  1. Gene therapy for HCV/HBV-induced hepatocellular carcinoma

    Current Opinion in Investigational Drugs, Vol. 11, Núm. 12, pp. 1368-1377